Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
Collegium (Nasdaq: COLL) will report fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026.
Rhea-AI Summary
Collegium (Nasdaq: COLL) will report fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET the same day. An audio webcast will be available on the Investors section of the company website and replayable approximately two hours after the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – COLL
On Feb 12, the day this news came out, COLL closed 0.31% above the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
Key Figures
- Earnings date
- February 26, 2026
- Q4 and full-year 2025 financial results release
- Call time
- 8:00 a.m. ET
- Scheduled live conference call and webcast start time
- US dial-in
- (877) 407-8037
- Domestic access number for earnings conference call
- International dial-in
- (201) 689-8037
- International access number for earnings conference call
- Webcast replay delay
- approximately two hours
- Time after event when replay becomes available online
Historical Context
-
Real‑world data posters on Jornay PM at APSARD 2026 conference.
-
Issued 2026 revenue and EBITDA guidance plus business update and credit facility detail.
-
Closed $980M syndicated credit facility and refinanced prior term loan.
-
Announced participation in multiple late‑2025 investor conferences with webcasts.
-
Reported record Q3 2025 results and raised full‑year 2025 guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Conference Call Information
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.